KDM5D and cancer: Furthermore, the use of MB49 tumor, spontaneously expressing H-Y as a neoantigen, allowed us to further elucidate the mechanisms of previously described clinical antitumor responses mediated by CD4 T cells specific to cancer neoantigens (2–4).